Positive Cream Formulation Results for SkinBiotix
- SkinBioTherapeutics announced that the ‘cream’ formulation of its SkinBiotix® technology has passed effectiveness studies conducted on models of skin. The cream formulation will now undergo further testing for stability in the coming weeks.
- The Company’s platform, SkinBiotix®, utilises extracts of probiotic bacteria for application to the skin. It has demonstrated in skin models that its technology can improve the skin’s barrier function (e.g. keep moisture in and protect skin from infection).
- The cream has been formulated to contain SkinBioTherapeutics’ proprietary technology, SkinBiotix®. A crucial feature of the formulation phase is to test that the cream-SkinBiotix® combination retains the same beneficial properties as the original technology.
- One important effect of SkinBiotix® in proof of concept studies was the increase of a specific skin protein essential to the barrier function of the skin. This effect was also shown when tested as a cream formulation. The data further showed a direct correlation between the amount of SkinBiotix® within the cream and the level of the protein present. Work on creating skin lotion and gel formulations is ongoing.
This represents a significant milestone in the development of products for the cosmetic market. The incorporation of SkInBiotix® technology into an effective cream formulation, subject to stability testing, should now permit SkinBioTherapeutics to create formulations for a human study later in 2018E.
COMPANY DESCRIPTION
Preclinical healthcare company focusing on skin health. The company is targeting three skin healthcare sectors: cosmetics, infection control and eczema.